Search Results
Results found for "Omass Therapeutics"
- Dr. Michel Bouvier | Dr. GPCR Ecosystem
of Canada (2014), the Julie Axelrod award from the American Society of Pharmacology and Exerimental Therapeutics
- Dr. Terry Hebert: How Cellular Background and Localization Influence GPCR Function | Dr. GPCR Ecosystem
Terry Hebert is a Professor of Pharmacology and Therapeutics at McGill University. The goal is to test therapeutic strategies targeting the AT1R, alpha-adrenergic, and beta-adrenergic
- FAQ | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- Dr. John Streicher: Reorganizing Opioid Signaling Beyond the Receptor | Dr. GPCR Ecosystem
Current lines of work include isoform-selective HSP90 inhibition as a strategy for widening the opioid therapeutic This is not a quirk — it is the central clue the lab has built a therapeutic strategy around.
- Scaling GLP 1 Receptor Tools Through Academia Industry Collaboration | Dr. GPCR Ecosystem
By integrating advanced tools and translational biology, his work directly informs therapeutic strategies
- Our History | Dr. GPCR Ecosystem
Sep 20, 2022 — First contributor article published: Therapeutic validation of an orphan G protein‐coupled
- GPCR Webinars | Dr. GPCR Ecosystem
Each session explores mechanistic models, translational challenges, and real-world therapeutic implications
- GPCR Masterclass: Advanced Pharmacology & Drug Discovery | Dr. GPCR
Unconventional GPCR Ligands <p class="font_8">Watch Now</p> Terry Kenakin The New Frontier of GPCR Therapeutics
- GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini | Dr. GPCR Ecosystem
analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic
- Hacking GPCRs: Tools, Tech & Drug Discovery with Tom Sakmar & Ilana Kotliar | Dr. GPCR Ecosystem
This could accelerate discovery of therapeutic targets by combining multiplex data with focused downstream
- When to Walk, When to Run: Lessons from the GPCR Trenches with Dr. Ben Clements | Dr. GPCR Ecosystem
Clements' work is primarily focused on translational developments of small molecule therapeutics, and
- Dr. Aaron Sato: Synthetic Antibody Libraries for the Hardest GPCR Targets | Dr. GPCR Ecosystem
record as a biologics leader as he led teams to discover and develop novel first-in-class antibody therapeutics
- Dr. Joseph Kim: Structural Biology and Drug Discovery at GPCRs | Dr. GPCR Ecosystem
structural biology and drug discovery, where molecular structures inform the design and development of new therapeutics You could easily imagine separate therapeutic programs targeting those different physiological effects
- Dr. Amynah Pradhan: The Delta Opioid Receptor and the Migraine Paradox | Dr. GPCR Ecosystem
Andrew Charles that who specialized in animal models of migraine and delta-opioid receptors as a therapeutic
- Dr. J. Silvio Gutkind: When GPCRs Drive Cancer | Dr. GPCR Ecosystem
The canonical assumption that targeting PLC would be therapeutic has failed in the clinic, and patients
- Dr. Foord: Serendipity, RAMPs, And Industrial GPCR Pharmacology | Dr. GPCR Ecosystem
Later hepatotoxicity concerns and the success of antibody therapeutics further shifted strategy.
- Dr. John Janetzko | Dr. GPCR Ecosystem
Over the course of my graduate work, I gained experience with structural mass spectrometry and protein My postdoc work has made use of several techniques including various mass spectrometry approaches, single
- Dr. Yamina Berchiche: Beyond the Lab — From Chemokine Receptors to the Dr. GPCR Ecosystem | Dr. GPCR Ecosystem
has reached only about 166 of them, leaving more than 250 receptors unstudied at anything close to therapeutic
- Revvity | Dr. GPCR Ecosystem
Whether you’re decoding signaling pathways or designing the next generation of therapeutics, Revvity
- Join the Dr. GPCR Affiliate Program - Empower the GPCR Community with Dr. GPCR Ecosystem Services
To be clear, commercializing, advertising, publishing, mass distributing, selling, or paying for the
- Dr. Anita Nivedha: Computational Dynamics of Ligand Bias in GPCR Signaling | Dr. GPCR Ecosystem
visualization to become quantitative tools for understanding receptor activation and guiding GPCR-targeted therapeutics
- Content Guidelines | Dr. GPCR Ecosystem
Spam Do not spam, including by sending unwanted promotional or commercial content, or mass solicitations
- Content and Conduct Policy | Dr. GPCR Ecosystem
Spam Do not spam, including by sending unwanted promotional or commercial content, or mass solicitations

















